Aim Immunotech Inc AIM

$0.18 -0.01 (-3.95%)

Valuation

Market cap
5,784,000
Revenue TTM
$90,000
Net income TTM
$-13,960,000
PE ratio
0.00
Forward PE
—
Profit margin
-15,511.11%
Debt to equity
0.00

Trading

Volume
672,500
Avg volume
5,877,646
Day's range
$0.18 – $0.19
Shares out
30,442,000
Stochastic %K
39%
Beta
1.27
Analysts
Sell
Price target
$4.25

Price

Company profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa)...

Show more

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
352 448 7797
Website
https://aimimmuno.com
Address
2117 SW Highway 484, Ocala, United States

Latest news

Stocktwits

bob397 Oct 7, 12:58 AM
$AIM Intellectual Property & Patent Expansions Long COVID Protection: AIM significantly expanded its global patent portfolio, securing patent protection in Europe and the United Kingdom covering Ampligen for Long COVID, extending exclusivity through June 2041. Oncology Combinations: The U.S. Patent and Trademark Office (USPTO) granted a broad patent covering the use of Ampligen in combination with pembrolizumab (Keytruda) for cancer treatment, protecting the IP landscape through 2039.
0 replies
jonjonson1234 Oct 6, 9:10 PM
$AIM HEB/AIM has routinely recycled old stale pumps when they think that their target market of naive investors has forgotten about them. Here is a story from 11 years ago about one of their earlier Ebola pumps. Back then it was Carter and Equels and now it is just Equels, but otherwise not much has changed with their Ebola pump. https://www.thestreet.com/investing/stocks/hemispherx-uses-ebola-tragedy-to-raise-cash-pay-executive-bonuses-13071620
2 replies
TheLionofwallstreet Oct 6, 5:37 PM
$AIM Ampligen probably works on the new plague...
1 replies
BioTuesdays Oct 6, 1:32 PM
$AIM is developing Ampligen, an immune modulator with potential applications across oncology, immune disorders, and viral diseases. The company is currently focused on developing Ampligen for late-stage pancreatic cancer, where AIM believes the therapy’s apparent ability to alter the tumor microenvironment could help address a significant unmet medical need. https://biotuesdays.com/2026/10/06/aim-advancing-immunology-solutions-for-globally-important-diseases/
1 replies
Paco5 Oct 6, 12:04 PM
$AIM as an Ebola cure?
1 replies
CoffeeRocks Oct 6, 9:45 AM
$QTEX $AIXI $AIM $RETO $SDEV AIXI
1 replies
CoffeeRocks Oct 6, 9:25 AM
$AIM $VRAX $ISPC $CODX $EBS Aim .19$S here buy
0 replies
ultimatebastos Oct 6, 7:47 AM
$AIM https://www.yahoo.com/news/world/articles/warmongering-putin-accused-massive-plague-204439039.html
0 replies